Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Scholar Rock Holding Corp (SRRK)
NASDAQ:SRRK
RESEARCH TOOLSreports
Holding SRRK?
Track your performance easily
Earnings Data
Report Date
Mar 11, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-0.6Last Year’s EPS
-0.5Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 08, 2018
|% Change Since: 53.21%
|Next Earnings Date:Aug 08, 2018
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress and success in clinical trials, financial strength, and strategic planning for regulatory and commercial milestones. While there is competitive pressure in the obesity market, the overall outlook is positive with robust clinical data and strong financial backing.Company Guidance
During the Scholar Rock Q3 2024 earnings call, significant guidance was provided regarding the company's progress and future plans. The company highlighted the success of its SAPPHIRE Phase III study for apitegromab in spinal muscular atrophy (SMA), which showed a 1.8-point improvement on the Hammersmith Functional Motor Scale with a p-value of 0.0192. Scholar Rock is on track to submit its Biologics License Application (BLA) and Marketing Authorization Application (MAA) in Q1 2025, aiming for a U.S. commercial launch in Q4 2025. Additionally, the EMBRAZE Phase II study with apitegromab completed enrollment ahead of schedule, with top-line results expected in Q2 2025. The company also expanded its management team and completed a $345 million follow-on offering, increasing its cash balance to approximately $463 million as of September 30, 2024. Scholar Rock is preparing for an ambitious commercial strategy, aiming for a potential revenue of over $1 billion from apitegromab, with plans to expand its anti-myostatin platform and enter the obesity treatment market.Successful SAPPHIRE Phase III Study
The pivotal Phase III SAPPHIRE study for apitegromab in spinal muscular atrophy met the primary endpoint with a 1.8 point improvement on the Hammersmith Functional Motor Scale, with a statistically significant p-value of 0.0192. 30% of patients on apitegromab achieved a 3-point improvement, compared to 12.5% for placebo.
Strong Financial Position
Scholar Rock completed an upsized follow-on offering of $345 million, leading to a pro forma September 30 cash balance of approximately $463 million, enabling them to scale up operations and focus on key priorities.
Regulatory and Commercial Preparation
Plans are in place to submit the BLA and MAA for apitegromab in Q1 2025, with a commercial launch anticipated in Q4 2025, assuming regulatory approval.
Advancements in Obesity Treatment
The nonclinical data for SRK-439, a novel anti-myostatin program in obesity, shows promising results in preserving lean muscle mass during weight loss, with plans to submit the IND by mid-2025.
---
SRRK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
SRRK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 12, 2024 | $28.15 | $26.66 | -5.29% |
| Aug 08, 2024 | $8.25 | $8.17 | -0.97% |
| May 07, 2024 | $15.06 | $14.69 | -2.46% |
| Mar 19, 2024 | $13.20 | $15.15 | +14.77% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Scholar Rock Holding Corp (SRRK) report earnings?
Scholar Rock Holding Corp (SRRK) is schdueled to report earning on Mar 11, 2025, TBA Not Confirmed.
What is Scholar Rock Holding Corp (SRRK) earnings time?
Scholar Rock Holding Corp (SRRK) earnings time is at Mar 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is SRRK EPS forecast?
SRRK EPS forecast for the fiscal quarter 2024 (Q4) is -0.6.
---